ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 169

New Autoinflammatory Phenotype Associated with Homozygous AGBL3 Variant

Ahmet Gül1, Neslihan Abaci2 and Sema Sirma Ekmekci2, 1Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 2Department of Genetics, Istanbul University Institute for Experimental Medical Research, Istanbul, Turkey

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Anakinra, Autoinflammatory Disease, C Reactive Protein, complement and genetic disorders

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Genetics, Genomics and Proteomics Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: To identify new genes/pathways associated with autoinflammatory phenotype.

Methods: We screened genomic variations by whole exome sequencing in 3 families presented with autoinflammatory findings despite negative results for known autoinflammatory gene mutations. A systematic search was carried out specifically for identification of deleterious genetic variants in genes involved in novel inflammatory pathways.

Results: We identified a deleterious mutation in the AGBL3 (ATP/GTP binding protein-like 3) gene, in a consanguineous family of Assyrian origin. Index case, now 22-year-old male, presented to our outpatient clinic with recurrent attacks of fever, urticarial rash on the extremities and trunk, conjunctival injections and arthralgia. His attacks started when he was 13, and two to three day lasting attacks recurred more frequently during warm weather conditions or following hot baths. He had highly elevated CRP and ESR during attacks, but his acute phase response did not return to normal values in between the flares. Low C3 and C4 values were also observed during asymptomatic periods. He responded partially to corticosteroids as well as canakinumab and anakinra treatments, and he is currently on low dose steroids and 200 mg/day anakinra. Whole exome sequencing revealed homozygous c.769C>T mutation in AGBL3 gene, which results in early termination of the protein (p.Gln257Ter) and deletion of carboxypeptidase domain. This protein belongs to metallocarboxypeptidases that mediate both deglutamylation and deaspartylation of target proteins. AGBL3 is suggested to catalyze the deglutamylation of polyglutamate side chains, especially in proteins such as tubulins. Also, STRING search revealed interaction of AGBL3 with complement regulatory proteins, such as CD46, CD55, and CD59, which are potent inhibitors of the complement membrane attack complex.

We searched databases from Turkey and other sources, and we could not identify this variant in other individuals.

Conclusion: This study identifies the AGBL3 metallocarboxypeptidase gene as a potential autoinflammatory gene involved in a novel pathway, and its loss of function mutations may result in a potent innate inflammatory response associated with lower complement levels and a partial response to IL-1 blockade.


Disclosure: A. Gül, None; N. Abaci, None; S. Sirma Ekmekci, None.

To cite this abstract in AMA style:

Gül A, Abaci N, Sirma Ekmekci S. New Autoinflammatory Phenotype Associated with Homozygous AGBL3 Variant [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/new-autoinflammatory-phenotype-associated-with-homozygous-agbl3-variant/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/new-autoinflammatory-phenotype-associated-with-homozygous-agbl3-variant/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology